Efficient cell culture system for hepatitis C virus genotype 5A
    2.
    发明授权
    Efficient cell culture system for hepatitis C virus genotype 5A 失效
    丙型肝炎病毒基因型5A的高效细胞培养系统

    公开(公告)号:US08618275B2

    公开(公告)日:2013-12-31

    申请号:US12600349

    申请日:2008-05-19

    摘要: The present inventors developed 5a/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and all of or part of NS2 were replaced by the corresponding genes of the genotype 5a reference strain SA13. Compared to the J6/JFH control virus, after transfection of in vitro transcripts in Huh7.5 cells, production of infectious viruses was delayed. However, in subsequent viral passages efficient spread of infection and HCV RNA titers as high as for J6/JFH were obtained. Infectivity titers were at all time points analyzed comparable to J6/JFH control virus. Sequence analysis of recovered 5a/2a recombinants from 2 serial passages and subsequent reverse genetic studies revealed adaptive mutations in p7, NS2 and/or NS3. Infectivity of the 5a/2a viruses was CD81 and SR-BI dependant, and the recombinant viruses could be neutralized by chronic phase sera from patients infected with genotype 5a. Conclusion: The developed 5a/2a viruses provide a robust in vitro tool for research in HCV genotype 5, including vaccine studies and functional analyses of an increasingly important genotype in South Africa and Europe.

    摘要翻译: 本发明人开发了5a / 2a基因型重组体,其中JFH1结构基因(Core,E1和E2),p7以及NS2的全部或部分被基因型5a参照菌株SA13的相应基因替代。 与J6 / JFH对照病毒相比,转染Huh7.5细胞体外转录本后,传染性病毒的产生延迟。 然而,在随后的病毒传代中,获得与J6 / JFH一样高的感染和HCV RNA滴度的有效扩散。 在与J6 / JFH对照病毒相比较的所有时间点,感染滴度。 来自2个连续传代和随后的反向遗传研究的回收的5a / 2a重组体的序列分析显示p7,NS2和/或NS3中的适应性突变。 5a / 2a病毒的感染率为CD81和SR-BI依赖性,重组病毒可以用来自感染基因型5a的患者的慢性期血清中和。 结论:开发的5a / 2a病毒为HCV基因型5的研究提供了强大的体外工具,包括南非和欧洲越来越重要的基因型的疫苗研究和功能分析。

    EFFICIENT CELL CULTURE SYSTEM FOR HEPATITIS C VIRUS GENOTYPE 1A AND 1B
    5.
    发明申请
    EFFICIENT CELL CULTURE SYSTEM FOR HEPATITIS C VIRUS GENOTYPE 1A AND 1B 有权
    有效的细胞培养系统用于丙型肝炎病毒基因组1A和1B

    公开(公告)号:US20110059513A1

    公开(公告)日:2011-03-10

    申请号:US12809345

    申请日:2008-12-19

    IPC分类号: C12N7/00 C07H21/04

    摘要: The present inventors developed hepatitis C virus 1a/2a and 1b/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and NS2 were replaced by the corresponding genes of the genotype Ia reference strain H77C or TN or the corresponding genes of the genotype Ib reference strain J4. Sequence analysis of recovered 1a/2a and 1b/2a recombinants from 2 serial passages and subsequent reverse genetic studies revealed adaptive mutations in e.g. p7, NS2 and/or NS3. In addition, the inventors demonstrate the possibility of using adaptive mutations identified for one HCV isolate in generating efficient cell culture systems for other isolates by transfer of mutations across isolates, subtypes or major genotypes. Furthermore neutralization studies showed that viruses of e.g. genotype 1 were efficiently neutralized by genotype Ia, 4a and 5a serum, an effect that could be utilized e.g. in vaccine development and immunological prophylaxis. The inventors in addition demonstrate the use of the developed systems for screening of antiviral substances in vitro and functional studies of the virus, e.g. identification of receptors required for HCV entry

    摘要翻译: 本发明人开发了丙型肝炎病毒1a / 2a和1b / 2a基因间重组体,其中JFH1结构基因(Core,E1和E2),p7和NS2被基因型1a参考菌株H77C或TN的相应基因替代,或 基因型1b参考菌株J4的相应基因。 来自2个连续传代和随后的反向遗传研究的回收的1a / 2a和1b / 2a重组体的序列分析揭示了例如, p7,NS2和/或NS3。 此外,本发明人证明了通过在分离株,亚型或主要基因型上转移突变,可以使用为一种HCV分离株鉴定的适应性突变来产生用于其他分离物的有效细胞培养系统。 此外,中和研究表明, 基因型1被基因型1a,4a和5a血清有效地中和,可以使用例如, 在疫苗开发和免疫预防中。 本发明人另外证明了所开发的系统在体外筛选抗病毒物质的用途和病毒的功能研究,例如, 鉴定HCV进入所需的受体

    Efficient cell culture system for hepatitis C virus genotype 7a
    7.
    发明授权
    Efficient cell culture system for hepatitis C virus genotype 7a 失效
    丙型肝炎病毒基因型7a高效细胞培养系统

    公开(公告)号:US08506969B2

    公开(公告)日:2013-08-13

    申请号:US13059137

    申请日:2009-07-31

    摘要: Genotype 7a has been identified recently, thus not much is known about the biology of this new, major HCV genotype. The present inventors developed hepatitis C virus 7a/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and the complete NS2 were replaced by the corresponding genes of the genotype 7a strain QC69 and characterized them in Huh7.5 cells. Sequence analysis of 7a/JFH1 recombinants recovered after viral passage in Huh7.5 cells following 4 independent transfection experiments revealed adaptive mutations in Core, E2, NS2, NS5A and NS5B. In reverse genetic studies the importance of these mutations for improved growth kinetics was shown. Adapted 7a/JFH1 viruses showed growth kinetics, infectivity and RNA titers comparable to a previously developed 3a/JFH1 reference virus. Conclusion: The developed 7a/JFH1 viruses provide a robust in vitro tool for research in HCV genotype 7, including vaccine studies and functional analyses.

    摘要翻译: 最近鉴定了基因型7a,因此对这种新的主要HCV基因型的生物学知之甚少。 本发明人开发了丙型肝炎病毒7a / 2a基因型重组体,其中JFH1结构基因(Core,E1和E2),p7和完整的NS2被基因型7a菌株QC69的相应基因替代,并在Huh7.5中表征 细胞。 在4次独立转染实验后Huh7.5细胞病毒传代后恢复的7a / JFH1重组体的序列分析显示核心,E2,NS2,NS5A和NS5B中的适应性突变。 在反向遗传研究中,显示了这些突变对改善生长动力学的重要性。 适应的7a / JFH1病毒显示与先前开发的3a / JFH1参考病毒相当的生长动力学,感染性和RNA滴度。 结论:开发的7a / JFH1病毒为HCV基因型7研究提供了强大的体外工具,包括疫苗研究和功能分析。

    INFECTIOUS GENOTYPE 1a, 1b, 2a, 2b, 3a, 5a, 6a and 7a HEPATITIS C VIRUS LACKING THE HYPERVARIABLE REGION 1 (HVR1)
    8.
    发明申请
    INFECTIOUS GENOTYPE 1a, 1b, 2a, 2b, 3a, 5a, 6a and 7a HEPATITIS C VIRUS LACKING THE HYPERVARIABLE REGION 1 (HVR1) 有权
    感染基因1a,1b,2a,2b,3a,5a,6a和7a HEPATITIS C VIRUS LACKING THE HYPERVARIABLE REGION 1(HVR1)

    公开(公告)号:US20120003719A1

    公开(公告)日:2012-01-05

    申请号:US13060533

    申请日:2009-08-07

    IPC分类号: C12N7/00 C12N5/10 C12N15/51

    摘要: The present inventors used the previously developed H77/JFH1T27OOC,A4O8OT (1a/2a), J4/JFH1T2996C,A4827T,ΔHVRI (1b/2a), J6/JFH1ΔHVRI (2a/2a), J8/JFH1ΔHVRI (2b/2a), S52/JFH1T27i8G,τ7i6oc (3a/2a), SA13/JFH1C34O5G,A3696G (5a/2a) and HK6a/JFH1T1389c,A1590G (6a/2a) constructs for the deletion of Hypervariable Region 1 (HVR1) to construct viable, JFH1 (geno-type 2a) based, genomes. The present inventors serially passaged the viruses in cell culture obtaining relatively high HCV RNA titers and infectivity titers. Sequence analysis of the viruses identified mutations adapting H77/JFH1T27OOC,A4O8OT,ΔHVR1 (1a/2a), J8/JFH1ΔHVR1 (2b/2a), S52/JFH1T2718G,T716OC,ΔHVR1 (3a/2a) and J4/JFH1T2996C,A4827T,ΔHVR1 (1b/2a) to the HVR1 deletion.

    摘要翻译: 本发明人使用先前开发的H77 / JFH1T27OOC,A4O8OT(1a / 2a),J4 / JFH1T2996C,A4827T,&Dgr; HVRI(1b / 2a),J6 / JFH1&Dgr; HVRI(2a / 2a),J8 / JFH1&Dgr; HVRI 2b / 2a),S52 / JFH1T27i8G,τ7i6oc(3a / 2a),SA13 / JFH1C34O5G,A3696G(5a / 2a)和HK6a / JFH1T1389c,用于缺失高变区1(HVR1)构建的A1590G(6a / 2a) 可行,基于JFH1(基因型2a)的基因组。 本发明人在细胞培养物中连续传代病毒获得相对高的HCV RNA滴度和感染滴度。 病毒的序列分析鉴定了H77 / JFH1T27OOC,A4O8OT,&Dgr; HVR1(1a / 2a),J8 / JFH1和Dgr; HVR1(2b / 2a),S52 / JFH1T2718G,T716OC,&Dgr; HVR1(3a / 2a)和J4 / JFH1T2996C,A4827T,&Dgr; HVR1(1b / 2a)至HVR1缺失。

    EFFICIENT CELL CULTURE SYSTEM FOR HEPATITIS C VIRUS GENOTYPE 7a
    9.
    发明申请
    EFFICIENT CELL CULTURE SYSTEM FOR HEPATITIS C VIRUS GENOTYPE 7a 失效
    HEPATITIS C病毒基因组的有效细胞培养系统7a

    公开(公告)号:US20110294195A1

    公开(公告)日:2011-12-01

    申请号:US13059137

    申请日:2009-07-31

    IPC分类号: C12N7/00 C12N5/10 C07H21/04

    摘要: Genotype 7a has been identified recently, thus not much is known about the biology of this new, major HCV genotype. The present inventors developed hepatitis C virus 7a/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and the complete NS2 were replaced by the corresponding genes of the genotype 7a strain QC69 and characterized them in Huh7.5 cells. Sequence analysis of 7a/JFH1 recombinants recovered after viral passage in Huh7.5 cells following 4 independent transfection experiments revealed adaptive mutations in Core, E2, NS2, NS5A and NS5B. In reverse genetic studies the importance of these mutations for improved growth kinetics was shown. Adapted 7a/JFH1 viruses showed growth kinetics, infectivity and RNA titers comparable to a previously developed 3a/JFH1 reference virus. Conclusion: The developed 7a/JFH1 viruses provide a robust in vitro tool for research in HCV genotype 7, including vaccine studies and functional analyses.

    摘要翻译: 最近鉴定了基因型7a,因此对这种新的主要HCV基因型的生物学知之甚少。 本发明人开发了丙型肝炎病毒7a / 2a基因型重组体,其中JFH1结构基因(Core,E1和E2),p7和完整的NS2被基因型7a菌株QC69的相应基因替代,并在Huh7.5中表征 细胞。 在4次独立转染实验后Huh7.5细胞病毒传代后恢复的7a / JFH1重组体的序列分析显示核心,E2,NS2,NS5A和NS5B中的适应性突变。 在反向遗传研究中,显示了这些突变对改善生长动力学的重要性。 适应的7a / JFH1病毒显示与先前开发的3a / JFH1参考病毒相当的生长动力学,感染性和RNA滴度。 结论:开发的7a / JFH1病毒为HCV基因型7研究提供了强大的体外工具,包括疫苗研究和功能分析。

    Efficient cell culture system for hepatitis C virus genotype 1A and 1B
    10.
    发明授权
    Efficient cell culture system for hepatitis C virus genotype 1A and 1B 有权
    丙型肝炎病毒基因型1A和1B的高效细胞培养系统

    公开(公告)号:US08563706B2

    公开(公告)日:2013-10-22

    申请号:US12809345

    申请日:2008-12-19

    摘要: The present inventors developed hepatitis C virus 1a/2a and 1b/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and NS2 were replaced by the corresponding genes of the genotype Ia reference strain H77C or TN or the corresponding genes of the genotype Ib reference strain J4. Sequence analysis of recovered 1a/2a and 1b/2a recombinants from 2 serial passages and subsequent reverse genetic studies revealed adaptive mutations in e.g. p7, NS2 and/or NS3. In addition, the inventors demonstrate the possibility of using adaptive mutations identified for one HCV isolate in generating efficient cell culture systems for other isolates by transfer of mutations across isolates, subtypes or major genotypes. Furthermore neutralization studies showed that viruses of e.g. genotype 1 were efficiently neutralized by genotype Ia, 4a and 5a serum, an effect that could be utilized e.g. in vaccine development and immunological prophylaxis. The inventors in addition demonstrate the use of the developed systems for screening of antiviral substances in vitro and functional studies of the virus, e.g. identification of receptors required for HCV entry.

    摘要翻译: 本发明人开发了丙型肝炎病毒1a / 2a和1b / 2a基因间重组体,其中JFH1结构基因(Core,E1和E2),p7和NS2被基因型1a参考菌株H77C或TN的相应基因替代,或 基因型1b参考菌株J4的相应基因。 来自2个连续传代和随后的反向遗传研究的回收的1a / 2a和1b / 2a重组体的序列分析揭示了例如, p7,NS2和/或NS3。 此外,本发明人证明了通过在分离株,亚型或主要基因型上转移突变,可以使用为一种HCV分离株鉴定的适应性突变来产生用于其他分离物的有效细胞培养系统。 此外,中和研究表明, 基因型1被基因型1a,4a和5a血清有效地中和,可以使用例如, 在疫苗开发和免疫预防中。 本发明人另外证明了所开发的系统在体外筛选抗病毒物质的用途和病毒的功能研究,例如, 鉴定HCV进入所需的受体。